Improving cancer detection using advanced PCR techniques
Official title: Significant expansion of spectral multiplexing in PCR
Funded at Lamprogen, INC. · NIH-10840378 · Data updated 2026-11-12
This study is working on a new way to improve a test that checks for multiple genetic markers at the same time, making it easier and quicker to diagnose cancer early, so patients can get the help they need faster.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lamprogen, INC. NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | June 1, 2023 |
| Project end | November 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $499,868 |
| NIH project number | 5R44GM150395-02 |
| Project ID | NIH-10840378 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals at risk for cancer who require genetic screening or diagnostic testing.
✕Less likely to help
Patients who have already been diagnosed with cancer and are not seeking further genetic testing may not benefit from this research.
What this research studies
This research focuses on enhancing the capabilities of real-time PCR to detect multiple genetic sequences simultaneously, which is crucial for early cancer diagnosis and screening. By developing a new method that allows for a significant increase in the number of sequences that can be analyzed at once, this project aims to make PCR more effective and accessible for clinical use. The approach seeks to combine the speed and cost-effectiveness of real-time PCR with the multiplexing capabilities typically associated with next-generation sequencing. This could lead to faster and more accurate diagnostic tests for cancer patients.
Why it matters
Potential benefit: If successful, this research could lead to more efficient and cost-effective cancer screening methods, improving early detection rates.
How similar studies have gone: Previous research has shown promise in enhancing PCR techniques for diagnostic purposes, indicating that this approach could build on established successes.
Where this research is happening
-
Lamprogen, INC.
Seattle, United States Active
Researchers
- Principal investigator: Yu, Jiangbo — Lamprogen, INC.
- Study coordinator: Yu, Jiangbo
Related research
Other NIH-funded projects on the same topics.
-
Deep profiling of tiny cells in tissue with ultra-bright dyes
A new imaging method aims to map many protein markers in tissue sections at once, helping doctors understand cancers and heart diseases better.
-
Developing advanced fluorescent nanoparticles for improved cell analysis
This study is working on a new type of tiny particles that can help doctors see and understand different types of cells in your body better, which could lead to more accurate tests and treatments for autoimmune diseases and cancers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.